Biovitrum AB (publ) will be listed under its new company name, Swedish Orphan Biovitrum AB (publ) with effect from June 24, 2010.
+-----------------------+------------+ |New short name: |SOBI | +-----------------------+------------+ |Unchanged ISIN code: |SE0000872095| +-----------------------+------------+ |Unchanged Round lot: |1 | +-----------------------+------------+ |Unchanged orderbook ID:|36316 | +-----------------------+------------+ For more information please contact: Swedish Orphan Biovitrum AB (publ) Erik Kinnman, EVP Investor Relations Phone: +46 73 422 15 40 [email protected] About Swedish Orphan Biovitrum Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO:BVT ) is listed on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com. Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on June 21, 2010 at 4 p.m. CET.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.